Resources from the same session
216MO - A randomized phase II trial of metronomic oral vinorelbine plus cyclophosphamide and capecitabine (VEX) vs weekly paclitaxel (P) as first- or second-line treatment in patients (pts) with ER+/HER2- metastatic breast cancer (MBC): The METEORA-II trial (IBCSG 54-16)
Presenter: Elisabetta Munzone
Session: Mini Oral session: Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast